CANDELA: Aflibercept 8 mg in Patients With nAMD

Wykoff CC, Brown DM, Reed K, et al

In the phase 2, randomized, single-masked, open-label, 44-week CANDELA trial, the authors investigated whether aflibercept 8 mg had greater therapeutic benefits compared with aflibercept 2 mg in patients with neovascular age-related macular degeneration.  Although the primary efficacy endpoint at week 16 was not met, trends in anatomic and visual improvements over 44 weeks with aflibercept 8 mg suggest additional therapeutic benefit over aflibercept 2 mg.